CTRI Number |
CTRI/2018/11/016365 [Registered on: 16/11/2018] Trial Registered Prospectively |
Last Modified On: |
04/04/2022 |
Post Graduate Thesis |
No |
Type of Trial |
Interventional |
Type of Study
|
Drug |
Study Design |
Randomized, Parallel Group Trial |
Public Title of Study
|
To assess the Safety and efficacy of clingen vaginal suppositories in patients with mixed vaginal infection |
Scientific Title of Study
|
A phase IV,double blind,comparative,Prospective,Multicentric study to assess safety and efficacy of fixed dose combination of clindamycin 100 mg and Clotrimazole 100 mg Vaginal suppositories (clingen) VS. Clotrimazole 100 mg vaginal suppositories in patients with mixed vaginal infection" |
Trial Acronym |
|
Secondary IDs if Any
|
Secondary ID |
Identifier |
AZ-C-ZIR-15-101 Version No.01 Dated 29th Nov 2016 |
Protocol Number |
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
Name |
Dr Manish Maladkar |
Designation |
Sr. Vice President Medical & Regulatory |
Affiliation |
Aristo Pharmaceuticals Pvt Ltd |
Address |
Aristo Pharmaceuticals Pvt Ltd 23A Shah Industrial Estate off Veera Desai Road Andheri West Mumbai
Mumbai (Suburban) MAHARASHTRA 400053 India |
Phone |
09820432880 |
Fax |
|
Email |
drmaladkar@outlook.com |
|
Details of Contact Person Scientific Query
|
Name |
Dr Shrikant Patil |
Designation |
asst GM |
Affiliation |
Aristo Pharmaceuticals Pvt Ltd |
Address |
Aristo Pharmaceuticals Pvt Ltd 23A Shah Industrial Estate off Veera Desai Road Andheri West Mumbai
Mumbai (Suburban) MAHARASHTRA 400053 India |
Phone |
09819304787 |
Fax |
|
Email |
shrikant.patil@aristopharma.org |
|
Details of Contact Person Public Query
|
Name |
Manisha Banavalikar |
Designation |
GM Clinical Research |
Affiliation |
AnaZeal Analyticals & Research Pvt Ltd |
Address |
AnaZeal Analyticals & Research Pvt Ltd
D 334 TTC Industrial Area MIDC Turbhe Navi Mumbai India
Mumbai (Suburban) MAHARASHTRA 400705 India |
Phone |
09892166748 |
Fax |
|
Email |
manishab@anazeal.com |
|
Source of Monetary or Material Support
|
Aristo Pharmaceuticals Pvt Ltd |
|
Primary Sponsor
|
Name |
Aristo Pharmaceuticals Pvt Ltd |
Address |
23 A,Shah Industrial Estate Off Veera Desai Road Andheri West Mumbai-400053 |
Type of Sponsor |
Pharmaceutical industry-Indian |
|
Details of Secondary Sponsor
|
|
Countries of Recruitment
|
India |
Sites of Study
|
No of Sites = 4 |
Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
DrSunesh Kumar |
All india Institute of medical Sciences |
All india Institute of medical Sciences Ansari nagar New Delhi-110029 New Delhi DELHI |
26594579
Kumar.sunesh@yahoo.com |
Dr Dattatray Sonwalkar |
KMRFS NIKOP HOSPITAL |
Ring road phaltan satara Satara MAHARASHTRA |
9423262300
nikophospital59@gmail.com |
Dr Kirankumar Nale |
KMRFS NIKOP HOSPITAL |
Ring road phaltan satara Satara MAHARASHTRA |
9822037374
nikophospital59@gmail.com |
DrDeepa Kala |
Terna Speciality Hospital |
Plot no. 12,Sec-22,Opp.Nerul Railway Station, Nerul (West),Navimumbai-400706. Thane MAHARASHTRA |
9820503082
dkala24@yahoo.com |
|
Details of Ethics Committee
Modification(s)
|
No of Ethics Committees= 4 |
Name of Committee |
Approval Status |
Institute Ethics Committee AIIMS, New Delhi, India |
Approved |
KMRFs Nikop institutional Ethics Committe |
Approved |
KMRFs Nikop institutional Ethics Committe |
Approved |
Terna Ethics Committee, Nerul |
Approved |
|
Regulatory Clearance Status from DCGI
|
|
Health Condition / Problems Studied
|
Health Type |
Condition |
Patients |
(1) ICD-10 Condition: N760||Acute vaginitis, |
|
Intervention / Comparator Agent
|
Type |
Name |
Details |
Comparator Agent |
Clotrimazole 100mg |
HS for 7 days |
Intervention |
FDC of CLINDAMYCIN 100 mg and Clotrimazole 100 mg |
HS for 7 days |
|
Inclusion Criteria
|
Age From |
18.00 Year(s) |
Age To |
80.00 Year(s) |
Gender |
Female |
Details |
1.Females 18 years of age or older.
2.Women with regular menstruation and visiting the trial centre from 5th day to 20th day of the cycle or post menopausal women (defined as women with absence of menstruation for at least 1 year from the date of screening.), or women with surgical menopause (oophorectomy, hysterectomy).
3. Female subjects screened positive for mixed vaginal infection based on two or more of the following microscopic findings
1) Yeasts or pseudohyphae on wet preparation (40 – 60% sensitivity) of vaginal discharge. – and/or Yeasts or pseudohyphae on Gram stain (up to 65% sensitivity) of vaginal discharge
2) Direct observation of the organism (T. vaginalis) by a wet smear (normal saline) or acridine orange stained slide from the posterior vaginal fornix (sensitivity 40-70% cases).
3) A Gram stain slide with Nugent score more than equal to 4.
And/or
(Amsel’s Diagnostic Criteria for Bacterial Vaginosis)
a) Off-white, thin, homogeneous discharge with little if any inflammation.
b) pH of vaginal fluid greater than 4.5, using pH paper that measures from 4.0 to 6.0
c) Positive whiff test for amine odour after addition of 10% KOH.
d) More than or equal to 20% Clue cells of the total epithelial cells on microscopic examination of the saline/wet mount.
4. Subjects who agree to refrain from the use of intra-vaginal products throughout the study (e.g., douches, feminine deodorant sprays, Spermicides, tampons, and diaphragms).
5. Capable of giving written informed consent.
6. Agree to no intercourse for 8 days from the day of start of treatment.
|
|
ExclusionCriteria |
Details |
1. Pregnant or lactating women.
2. Patients receiving neuromuscular blocking agents.
3. Patients having history of hypersensitivity to Clindamycin or Clotrimazole.
4. Patients with history of regional enteritis, ulcerative colitis, pseudo-membranous colitis or history
of antibiotic associated colitis.
5. Women receiving any antibiotic treatment 14 days prior to enrolment.
6. Female patient of child bearing potential who do not agree to remain abstinent or use medically acceptable methods of contraception during the study therapy.
7. Patients who have participated in any clinical trial in the past 3 month.
8. History of significant cardiovascular disorders or primary or secondary immunodeficiency.
9. Any other condition that in the opinion of the Investigator does not justify the patient’s participation in the study.
10. Presence of vaginal / vulval ulcer or any other vulval, vaginal or medical condition, including cervical neoplasia/ treatment that might confound treatment response.
11. Inability to keep return appointments
12. Presence of intrauterine device.
13. Patients who do not agree to stop use of any other antibacterial, antifungal or anti protozoal drug during trial period.
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
Method of Concealment
|
Sequentially numbered, sealed, opaque envelopes |
Blinding/Masking
|
Participant and Investigator Blinded |
Primary Outcome
|
Outcome |
TimePoints |
• The primary efficacy endpoint is the therapeutic cure which requires both clinical cure and pathogen eradication confirmed by microbiological vaginal swab testing and Nugent score of 0-3 at last visit.
• Safety endpoints (adverse events, vital signs).
|
visit 1 visit 2 visit 3 visit 4 |
|
Secondary Outcome
|
Outcome |
TimePoints |
• The secondary efficacy endpoints are
a) Time to resolution of symptoms.
b) Change in lab parameters compared to baseline. (CBC, ESR, LFT(SGPT (ALT), SGOT (AST), S. Bilirubin (TOTAL), S. Bilirubin (DIRECT), RFT (Serum Creatinine, BUN) , urine routine and microscopic and BSL (Random). |
Visit 1 and Visit 4 |
|
Target Sample Size
|
Total Sample Size="300" Sample Size from India="300"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
Phase of Trial
|
Phase 4 |
Date of First Enrollment (India)
|
22/11/2018 |
Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
Date of First Enrollment (Global) |
Date Missing |
Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
Estimated Duration of Trial
|
Years="2" Months="6" Days="1" |
Recruitment Status of Trial (Global)
Modification(s)
|
Not Applicable |
Recruitment Status of Trial (India) |
Open to Recruitment |
Publication Details
|
None yet |
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
|
Brief Summary
|
Vaginitis
is an inflammation of the vagina. One third of women will have symptoms of Vaginitis.
It affects women’s of all ages but is most common during the reproductive years.
A change in balance of the yeast and bacteria that normally live in the vagina can
result in vaginitis. This causes lining of vagina to become inflamed. Factors
that can change the normal balance of vagina include: Use of antibiotics, Change
in hormone level due to pregnancy, breastfeeding or menopause, douching, spermicides,
sexual intercourse and infection. Treatment will depend on the cause of
vaginitis. Treatment may be either with pill or a cream or a gel that is
applied to vagina. Bacterial vaginitis is caused by overgrowth of bacteria that
occur naturally in vagina main symptom is increased discharge with strong fishy
odour the discharge usually is thin and dark or dull gray but may have a
greenish color. Itching is not common but may be present if there is lot of
discharge. Several different antibiotics can be used to treat Bacterial Vaginosis.
One of them is Clindamycin.
A
yeast infection is caused by fungus called Candida. It is found in small
numbers in the normal vagina. However when the balance of the bacteria and
yeast in the vagina is adhered, the yeast may overgrow and causes symptoms. Use
of some type of antibiotics increases your risk of yeast infection. The
antibiotics kill natural vaginal bacteria, which keeps yeast in check. The
yeast can then overgrow. Most common symptoms of yeast infection are itching
and burning of the area outside the vagina called vulva. The vulva may be red
and swollen. The vaginal discharge is usually white, lumpy and has no odour.
Some women with yeast infection notice an increase or change in discharge. Trichomoniasis
is condition caused by microscopic parasite Trichomonas vaginalis. it is spread
through sex. Signs may include a yellow gray or green vaginal discharge. The
discharge may have fishy odour. There may be burning,
Irritation, redness and swelling of vulva. Sometimes there is pain during
urination.
Clindamycin
is an antibacterial agent, kills bacteria by inhibiting bacterial protein
synthesis by affecting the process of peptide chain initiation. Clindamycin has
excellent activity against many anaerobes as well as aerobic gram-positive Cocci.
It exhibits anti bacterial activity against most of the organisms that that
have been associated with bacterial5.
Clotrimazole
is an imidazole with broad spectrum antifungal action it inhibits fungal cell
wall synthesis by inhibiting synthesis of ergosterol, an important component of
cell wall which alters the permeability of cell membrane of sensitive fungi and
leads to structural and functional impairment of the cyctoplasmic membrane. Clotrimazole
has fungicidal action against Candida albicans and trichomonocidal action5.
Clingen suppositories are available
in India by Aristo Pharmaceuticals for
last 10 years. Periodic safety and efficacy of the fixed dose combination is to
be assessed. Clingen is indicated in mixed vaginal infections including
Bacterial Vaginosis, Vaginal Candidiasis, Trichomoniasis; infective leucorrhea
and non-specific vaginitis. The aim of the present study is to generate safety
and efficacy data of Clingen suppositories in clinical condition of mixed Vaginitis
in Indian population over a single drug treatment of clotrimazole suppositories.
This Clinical Study is “A phase IV, double blind, prospective, comparative,
randomized, multicentric study to assess safety and efficacy of fixed dose
combination of Clindamycin (100 mg) and Clotrimazole (100 mg) vaginal
suppositories (Clingen) compared to clotrimazole (100 mg) vaginal suppositories
in patients with mixed vaginitis.†proposed to be conducted in the Indian
population as per the requirement of schedule Y of Drugs & Cosmetic rules 2005, under the NOC of Drugs
Controller General of India (DCGI), for retaining permission of Manufacturing
& Marketing of Clingen suppositories
in India. |